01 / 20

Neurodegenerative
Disease Management

A clinical approach to diagnosing and managing Alzheimer's, Parkinson's, and related disorders in the outpatient and longitudinal setting.

USMLE Step 3

What Is Neurodegeneration?

Neurodegenerative diseases are characterized by the progressive loss of structure or function of neurons, often driven by abnormal protein aggregation. They are chronic, irreversible, and progressive.

Key Players

Amyloid-β & Tau
Plaques and neurofibrillary tangles in Alzheimer's disease.
α-Synuclein
Lewy bodies in Parkinson's and Lewy body dementia.
Dopamine Loss
Substantia nigra degeneration drives parkinsonism.

Disease Progression Curve

Function Time (years) Early Dx Mild-Mod Advanced

Core Rule: Alzheimer's Pharmacotherapy

1
Mild to moderate: Start a cholinesterase inhibitor — donepezil, rivastigmine, or galantamine.
2
Moderate to severe: Add memantine (NMDA receptor antagonist) for additive benefit.
3
Non-pharmacologic: Caregiver support, structured environment, treat reversible contributors.

Core Rule: Parkinson's Pharmacotherapy

Treatment is symptomatic and centered on restoring dopaminergic tone. The relationship between symptom severity and drug choice can be modeled as a threshold-driven escalation:

Distinguishing AD vs PD Dementia

Alzheimer's Parkinson / Lewy Body
Early featureMemory lossMotor symptoms / visual hallucinations
Cognition timingCognitive firstMotor first (PDD), or concurrent (DLB)
Antipsychotic riskModerateSevere sensitivity
First-line drugCholinesterase inhibitorLevodopa / dopamine agonist

How to Apply It

1
Confirm the diagnosis. Rule out reversible causes (B12, thyroid, depression, medication effects).
2
Stage severity. Use cognitive scales (MMSE/MoCA) or motor scales (UPDRS).
3
Match therapy to disease and stage. Choose drug class per the core rules.
4
Manage behavior and safety. Address falls, driving, BPSD, and caregiver burden.
5
Reassess and titrate. Monitor adverse effects and adjust longitudinally.

Worked Example: Early AD

A 72-year-old woman has 18 months of progressive short-term memory loss. MMSE is 22/30. Labs and MRI exclude reversible causes.

MMSE 22 Mild AD Donepezil (ChEI) + caregiver support

Worked Example: Advancing PD

A 78-year-old man with Parkinson's has worsening bradykinesia limiting his independence. He already takes a low-dose dopamine agonist.

Worked Example: Behavioral Crisis

A patient with Lewy body dementia develops agitation and visual hallucinations. The nursing facility requests an antipsychotic.

Common Mistakes

✕ Skipping the workup
Treating dementia without excluding B12 deficiency, hypothyroidism, or depression.
✕ Wrong staging match
Starting memantine in mild AD or adding levodopa too early in young PD patients.
✕ Typical antipsychotics
Using haloperidol in Lewy body dementia, risking severe neuroleptic sensitivity.
✕ Ignoring caregivers
Neglecting caregiver burden and safety planning (falls, driving, wandering).

Management Summary

Scenario First-Line Add / Avoid
Mild-mod ADCholinesterase inhibitorAdd memantine if severe
Severe ADChEI + memantineMaximize support
Young / mild PDDopamine agonist / MAO-BDelay levodopa
Older / disabling PDLevodopa-carbidopaWatch dyskinesia
Lewy body + agitationTreat triggers, ChEIAvoid typicals

Check Your Understanding

Question 1 of 5

A 70-year-old man with newly diagnosed mild Alzheimer's disease (MMSE 24) and no comorbidities should be started on which agent?

Question 2 of 5

An 80-year-old woman with Parkinson's disease has disabling bradykinesia despite a dopamine agonist. What is the most effective next step?

Question 3 of 5

In a patient with Lewy body dementia and agitation, which medication is most dangerous and should be avoided?

Question 4 of 5

Before starting therapy for a patient with suspected dementia, which step is essential?

Question 5 of 5

A patient with moderate-to-severe Alzheimer's on donepezil continues to decline. What is the most appropriate addition?

You've Got the Framework